Skip to main content




Leeftijd icoon
55 - 85 years
Diagnose icoon
Mild to moderate stage Alzheimer’s disease
Duratie onderzoek
58 weeks
Locatie icoon
Amsterdam, Den Bosch and Zwolle

About this research

In order to participate in this study, you must be able to speak and read Dutch fluently. 

The goal of this study is to evaluate how safe and effective the new drug GV1001 is for the treatment of participants with mild to moderate stage Alzheimer’s Disease. The study compares the effect of the new drug GV1001 with the effect of a placebo (a drug without an active ingredient, a ‘fake drug’). The study drug is administered through a subcutaneous injection.

Originally GV1001 was developed as a drug to treat different types of cancer. However, some explorative studies showed that this drug improved cognitive functioning and memory. It also decreased levels of amyloid beta and tau proteins, which are associated to Alzheimer’s by many researchers. This study thus investigates to what extent this drug is effective for people with Alzheimer’s. To participate in this research, participants must have elevated levels of amyloid protein in the brain. If this is not known at the start of the study, some tests will be conducted to determine the presence of amyloid in the brain.

You and your study partner, someone who knows you well and can answer questions about your daily functioning, will visit the research center approximately 30 times, during approximately 58 weeks. In addition, you will also have several telephone conversations. The duration of a visit is not always the same because not every visit has the same procedures. Some of these visits may last 6 hours, others 3.5 hours. A phone call takes around 15 minutes. The research takes place in Amsterdam, Den Bosch, and Zwolle.

This research is commissioned by GemVax.

How does the application process go?

You always decide whether you participate in a study. Participation is always voluntary.

  1. You apply via the online form, this is non-binding.
  2. After application, you are phoned, this is also an opportunity for you to ask questions. During this conversation, we also ask some questions to see whether you are eligible to participate in research. After this conversation, you determine whether you want to progress to step 3.
  3. You receive an email with the request to sign a document in which you give permission to retrieve your medical data.
  4. When your medical data shows that you meet the requirements to participate in the study, you are invited to a meeting at our location. During this meeting, you receive information and have the opportunity to ask questions, before you decide to participate in research.
  5. If you decide to participate in the study, you sign a form and will start the study within several weeks.

What are the benefits of Brain Research Center?

  1. You always come first – everything we do revolves around you.
  2. Experienced team of doctors, neuropsychologists, and nurses.
  3. Open and homely atmosphere – this will make you feel relaxed and right at home.
  4. Clarity – expert in medicine research which is why you will be well informed during all steps of the process and can always come to us for questions.
  5. Always nearby – 3 locations spread through the Netherlands.

What's in it for me?

  • You may experience benefits from a new treatment.
  • You will be monitored by a specialized team of healthcare professionals. They can give you advice and monitor whether there is a change in your daily functioning.
  • You make a meaningful contribution to a future without Alzheimer’s.
  • You contribute to the advancement of science.

Can I participate?

You can participate when:

  • You have a mild to moderate stage Alzheimer’s disease
  • You are older between 55 and 85 years old
  • You have someone close to you/a caregiver who can accompany you during the visits to the research center and can answer questions about your health and functioning, among other things.

Are you unsure whether you meet these requirements? Then you can always apply. We will then check together whether you are suitable to participate. 

Take action against Alzheimer’s. Sign up to participate.

Latest Dementia trials